清宁口服液治疗老年慢性阻塞性肺疾病肺动脉高压的临床观察

目的：评价清宁口服液治疗老年慢性阻塞性肺疾病（ｃｈｒｏｎｉｃ ｏｂｓｔｒｕｃｔｉｖｅ ｐｕｌｍｏｎａｒｙ ｄｉｓｅａｓｅ，ＣＯＰＤ）肺动脉高压的临床疗效。方法：４０例老年ＣＯＰＤ并肺动脉高压（肺阻抗测定肺动脉平均压≥２．６７ｋＰａ）患者随机分为治疗组（清宁口服液每桨２０ｍｌ，每日３次，口服３０天）和对照组（除不给予清宁口服液外，其他治疗与治疗组相同）。治疗前后均进行心肺阻抗、血气分析，体循环血压、

Clinical Study on Qingning Oral Liquid in Treating Senile Chronic Obstructive Pulmonary Disease with Pulrmary Hypertension

OBJECTIVE: To evaluate the clinical effect of Qingning Oral Liquid (QNOL) in treating senile chronic obstructive pulmonary disease (COPD) with pulmonary hypertension. METHODS: Forty patients with mean pulmonary artery pressure (mPAP) more than 2.67 kPa (by impedance rheogram) were divided randomly into two groups. Twenty cases of QNOL group treated by conventional therapy with QNOL cases ml three times a day for 30 days and the other 20 cases treated with conventional therapy alone were taken as control group. Impedance cardiogram and pheopneumogram, blood gas analysis, mean systemic arterial pressure (mSAP), plasma tissue plasminogen activator(tpA) and plasminogen a ctivator inhibitor (PAI) activity were examined before and after treatment. RESULTS: After treatment, the mPAP of QNOL group lowered for 23.80 +/- 2.31%, the cardiac output, stroke volume and cardiac index of patients were improved, tPA activity elevated and PAI activity decreased. As compared with before treatment and the control group, these changes were significant statistically. The mSAP, PaO2 and PaCO2 were not significantly changed after treatment (P > 0.05). The change of mPAP showed negatively correlated with tPA activity (r = -0.554) and positively correlated with PAI activity (r = 0.608, P < 0.05). CONCLUSIONS: QNOL has a selective effect on pulmonary hypertension, its mechanism might be correlated to the elevating plasma tPA and the lowering of PAI activity.